CARsgen Therapeutics Holdings Limited has announced the results of an investigator-initiated trial for CT071, an autologous CAR T-cell product targeting GPRC5D, aimed at treating newly diagnosed multiple myeloma. These research findings were presented as a poster at the 30th Annual Congress of the European Hematology Association on June 13, 2025. The company has made the announcement on a voluntary basis to inform shareholders and potential investors about this latest business update. Further details regarding the research results can be found on CARsgen's corporate website.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CARsgen Therapeutics Holdings Ltd. published the original content used to generate this news brief on June 16, 2025, and is solely responsible for the information contained therein.